BRPI0710959B8 - uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular. - Google Patents

uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.

Info

Publication number
BRPI0710959B8
BRPI0710959B8 BRPI0710959A BRPI0710959A BRPI0710959B8 BR PI0710959 B8 BRPI0710959 B8 BR PI0710959B8 BR PI0710959 A BRPI0710959 A BR PI0710959A BR PI0710959 A BRPI0710959 A BR PI0710959A BR PI0710959 B8 BRPI0710959 B8 BR PI0710959B8
Authority
BR
Brazil
Prior art keywords
prevention
treatment
secretory
fragments
manufacture
Prior art date
Application number
BRPI0710959A
Other languages
English (en)
Portuguese (pt)
Inventor
Jennische Eva
Hansson Hans-Arne
Lange Stefan
Original Assignee
Lantmaennen As Faktor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lantmaennen As Faktor Ab filed Critical Lantmaennen As Faktor Ab
Publication of BRPI0710959A2 publication Critical patent/BRPI0710959A2/pt
Publication of BRPI0710959B1 publication Critical patent/BRPI0710959B1/pt
Publication of BRPI0710959B8 publication Critical patent/BRPI0710959B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI0710959A 2006-04-27 2007-04-27 uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular. BRPI0710959B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0600932-8 2006-04-27
SE0600932 2006-04-27
PCT/SE2007/000414 WO2007126364A2 (en) 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension

Publications (3)

Publication Number Publication Date
BRPI0710959A2 BRPI0710959A2 (pt) 2012-02-28
BRPI0710959B1 BRPI0710959B1 (pt) 2018-11-06
BRPI0710959B8 true BRPI0710959B8 (pt) 2021-05-25

Family

ID=38561776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710959A BRPI0710959B8 (pt) 2006-04-27 2007-04-27 uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.

Country Status (18)

Country Link
US (2) US8207296B2 (cg-RX-API-DMAC7.html)
EP (2) EP2015767B1 (cg-RX-API-DMAC7.html)
JP (2) JP5284948B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090040404A (cg-RX-API-DMAC7.html)
CN (2) CN102633863B (cg-RX-API-DMAC7.html)
AU (1) AU2007244004B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0710959B8 (cg-RX-API-DMAC7.html)
CA (2) CA2771087C (cg-RX-API-DMAC7.html)
DK (2) DK2468292T3 (cg-RX-API-DMAC7.html)
ES (2) ES2561945T3 (cg-RX-API-DMAC7.html)
IL (1) IL194773A (cg-RX-API-DMAC7.html)
MX (1) MX2008013769A (cg-RX-API-DMAC7.html)
NZ (2) NZ572255A (cg-RX-API-DMAC7.html)
PL (2) PL2015767T3 (cg-RX-API-DMAC7.html)
RU (1) RU2458703C2 (cg-RX-API-DMAC7.html)
SG (1) SG171602A1 (cg-RX-API-DMAC7.html)
WO (1) WO2007126364A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200809115B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
US9962424B2 (en) 2007-04-27 2018-05-08 Lantmännen As-Faktor Ab Use of antisecretory factors (AF) for optimizing cellular uptake
EP2396024A4 (en) * 2009-02-11 2013-02-27 Lantmaennen As Faktor Ab USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
WO2013050795A1 (en) * 2011-10-03 2013-04-11 Femtonics Kft. Use of photoactive compounds
WO2014096384A1 (en) * 2012-12-20 2014-06-26 Lantmännen As-Faktor Ab Use of antisecretory factor (af) in glioblastoma treatment
JP6707121B2 (ja) 2015-07-10 2020-06-10 ラントメネン・アーエス−ファクトール・アーベー 高含量のａｆ−１６を有する卵黄の産生方法
MX2019000594A (es) 2016-07-18 2019-09-09 Lantmaennen As Faktor Ab Factor anti-secretor 17.
JP7217760B2 (ja) 2018-06-28 2023-02-03 ラントメネン・メディカル・アーベー 急性呼吸不全の治療および／または予防の使用のための抗分泌因子
EP3855935A1 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted wheat
EP3855934A2 (en) 2018-09-28 2021-08-04 Lantmännen Functional Foods AB A consumable product comprising malted dehulled oat
CN115605214A (zh) 2020-03-26 2023-01-13 兰特门内保健食品公司（Se） 用于促进身体活动恢复的包含麦芽化谷物的可消耗产品
WO2024102346A1 (en) * 2022-11-08 2024-05-16 Aisa Pharma, Inc. Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH682716A5 (de) 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
JP2000506375A (ja) * 1996-01-26 2000-05-30 エイチエスシー リサーチ アンド デベロップメント リミテッド パートナーシップ アルツハイマー病に関連する核酸およびタンパク質、ならびにその使用
SE506486C2 (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
MXPA01001885A (es) * 1999-06-21 2002-04-24 Inkine Pharmaceutical Company Angiocidina: un receptor de adhesion a celula tumoral especifico de cys-ser-val-thr-cys-gly.
RU2192898C1 (ru) * 2001-08-16 2002-11-20 Московский научно-исследовательский институт глазных болезней им. Гельмгольца Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
AU2007244005B2 (en) * 2006-04-27 2012-08-02 Lantmannen As-Faktor Ab Further medical uses of antisecretory protein
SG171602A1 (en) * 2006-04-27 2011-06-29 Lantmaennen As Faktor Ab Use of antisecretory factors for treating intraocular hypertension
CN101460187B (zh) * 2006-04-27 2014-11-05 兰特门内阿斯-法克托尔公司 抗分泌蛋白的进一步医疗应用

Also Published As

Publication number Publication date
KR20090040404A (ko) 2009-04-24
CA2771087A1 (en) 2007-11-08
JP2012153695A (ja) 2012-08-16
US20120283191A1 (en) 2012-11-08
NZ572255A (en) 2012-03-30
CN101432013B (zh) 2015-01-07
IL194773A (en) 2015-07-30
ZA200809115B (en) 2009-07-29
US20090162296A1 (en) 2009-06-25
DK2468292T3 (da) 2020-03-23
BRPI0710959A2 (pt) 2012-02-28
CA2650344A1 (en) 2007-11-08
CN101432013A (zh) 2009-05-13
CN102633863A (zh) 2012-08-15
RU2458703C2 (ru) 2012-08-20
AU2007244004A1 (en) 2007-11-08
WO2007126364A2 (en) 2007-11-08
MX2008013769A (es) 2009-02-03
JP2009535329A (ja) 2009-10-01
NZ598426A (en) 2012-08-31
EP2468292B8 (en) 2020-02-26
CA2771087C (en) 2016-03-15
US9000125B2 (en) 2015-04-07
SG171602A1 (en) 2011-06-29
AU2007244004B2 (en) 2012-02-09
IL194773A0 (en) 2011-08-01
DK2015767T3 (en) 2016-02-08
CA2650344C (en) 2017-10-31
CN102633863B (zh) 2014-08-06
JP5284948B2 (ja) 2013-09-11
EP2468292A1 (en) 2012-06-27
BRPI0710959B1 (pt) 2018-11-06
RU2008146733A (ru) 2010-06-10
EP2468292B1 (en) 2019-12-18
EP2015767A2 (en) 2009-01-21
US8207296B2 (en) 2012-06-26
WO2007126364A3 (en) 2008-03-06
PL2015767T3 (pl) 2016-05-31
PL2468292T3 (pl) 2020-08-24
EP2015767B1 (en) 2016-01-06
ES2773945T3 (es) 2020-07-15
ES2561945T3 (es) 2016-03-01
WO2007126364A8 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
BRPI0710959B8 (pt) uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.
BRPI0607447A2 (pt) solução oftálmica de bimatoprost aprimorada
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
BR112013017002A2 (pt) "proteínas mic não naturais, seu uso no tratamento de malignalidade ou infecção viral, bem como composição compreendendo as referidas proteínas"
BRPI0408690A (pt) composto, método para tratamento de uma doença, composição farmacêutica, e, uso de um composto
MX2009007065A (es) Variantes de desintegrina y usos farmaceuticos de los mismos.
CR9807A (es) Uso de derivados de azabiciclohexano
BR112012015188A8 (pt) composição e método para o tratamento e/ou a prevenção de uma doença ocular relacionada à angiogênese
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
ATE359794T1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
ATE508711T1 (de) Vorgeformter intrastromaler hornhauteinsatz für hornhautanomalien oder -dystrophien
WO2007054257A3 (en) Indene derivatives, their preparation and use as medicaments
BR112022016528A2 (pt) Anticorpo antiadrenomedulina (adm) ou fragmento de anticorpo anti-adm ou scaffold anti-adm não ig para uso em terapia ou prevenção de choque
WO2006044425A3 (en) Ophthalmic compositions for treating ocular hypertension
WO2004043354A3 (en) Ophthalmic compositions for treating ocular hypertension
BRPI0519355A2 (pt) compostos para tratamento contra flaviviridae
IL267555A (en) Ostraulicin, a functionally related variette, an extract containing ostraulicin and its uses
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2004087734A3 (en) Stq-peptides
CN110891597A (zh) 防治家禽滑膜霉浆菌感染的组合物
ATE506961T1 (de) Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
MX2021011183A (es) Fitoecdisonas y los derivados de las mismas para su uso en el tratamiento de la alteracion de la funcion respiratoria.
BR112022019403A2 (pt) Uso de um derivado de tienopiridona no tratamento de doença renal policística autossômica dominante (drpad)
WO2006020003A3 (en) Ophthalmic compositions for treating ocular hypertension

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2668 DE 22-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.